BAMS
NBIX icon

Bellevue Asset Management (Switzerland)’s Neurocrine Biosciences NBIX Stock Holding History

Bellevue Asset Management (Switzerland)’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		$3.68M Hold
65,000
– – 0.56% 57
2015
Q3 		$2.59M Hold
65,000
– – 0.42% 74
2015
Q2 		$3.1M Buy
65,000
+25,000
+63% +$1.06M 0.43% 71
2015
Q1 		$1.59M Buy
+40,000
New +$1.43M 0.22% 101

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s NBIX Position: Q4 2015 in Review

Bellevue Asset Management (Switzerland) held its Neurocrine Biosciences (NBIX) position steady in Q4 2015 at 65,000 shares worth $3.68M. The position accounts for 0.56% of the portfolio, ranked #57.

Bellevue Asset Management (Switzerland) first reported a position in NBIX in Q1 2015 and has held it in 4 quarters since. 219 funds tracked by Wall St. Rank hold NBIX as of Q4 2015.

  • Bellevue Asset Management (Switzerland) held 65,000 shares of Neurocrine Biosciences worth $3.68M as of Q4 2015.
  • Bellevue Asset Management (Switzerland) left its Neurocrine Biosciences share count unchanged in Q4 2015.
  • Neurocrine Biosciences made up 0.56% of Bellevue Asset Management (Switzerland)'s portfolio in Q4 2015, its #57 holding.
  • Bellevue Asset Management (Switzerland) first reported a position in Neurocrine Biosciences in Q1 2015 and has held it in 4 quarters since.
  • 219 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2015.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q4 2015, filed 12 Feb 2016.